Understanding the Monoclonal Antibody Disposition after Subcutaneous Administration using a Minimal Physiologically based Pharmacokinetic Model

被引:44
|
作者
Varkhede, Ninad [1 ]
Forrest, M. Laird [1 ]
机构
[1] Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66047 USA
来源
JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES | 2018年 / 21卷 / 01期
关键词
NECROSIS-FACTOR-ALPHA; PBPK MODEL; POPULATION PHARMACOKINETICS; LYMPHATIC TRANSPORT; HEALTHY JAPANESE; INJECTION SITES; PHASE-I; SINGLE; SAFETY; PREDICT;
D O I
10.18433/jpps30028
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: Monoclonal antibodies (mAbs) are commonly administered via subcutaneous (SC) route. However, bioavailability is often reduced after SC administration. In addition, the sequential transfer of mAbs through the SC tissue and lymphatic system is not completely understood. Therefore, major objectives of this study were a) To understand absorption of mAbs via the lymphatic system after SC administration using physiologically based pharmacokinetic (PBPK) modeling, and b) to demonstrate application of the model for prediction of SC pharmacokinetics (PK) of mAbs. Methods: A minimal PBPK model was constructed using various physiological parameters related to the SC injection site and lymphatic system. The remainder of the body organs were represented using a 2-compartment model (central and peripheral compartments), with parameters derived from available intravenous (IV) PK data. The W and SC clinical PK data of a total of 10 mAbs were obtained from literature. The SC PK data were used to estimate the lymphatic trunk-lymph node (LN) clearance. Results: The mean estimated lymphatic trunk-LN clearance obtained from 37 SC PK profiles of mAbs was 0.00213 L/h (0.001332 to 0.002928, 95% confidence intervals). The estimated lymphatic trunk-LN clearance was greater for the mAbs with higher isoelectric point (pl). In addition, the estimated clearance increased with decrease in the bioavailability. Conclusion: The minimal PBPK model identified SC injection site lymph flow, afferent and efferent lymph flows, and volumes associated with the SC injection site, lymphatic capillaries and lymphatic trunk-LN as important physiological parameters governing the absorption of mAbs after SC administration. The model may be used to predict PK of mAbs using the relationship of lymphatic trunk-LN clearance and the pI. In addition, the model can be used as a bottom platform to incorporate SC and lymphatic in vitro clearance data for mAb PK prediction in the future.
引用
收藏
页码:130S / 148S
页数:19
相关论文
共 50 条
  • [21] Physiologically Based Pharmacokinetic Model of Midazolam Disposition during Pregnancy
    Andrew, Marilee A.
    Hebert, Mary F.
    Vicini, Paolo
    2008 30TH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY, VOLS 1-8, 2008, : 5454 - +
  • [22] Physiologically Based Pharmacokinetic/Pharmacodynamic Model for Caffeine Disposition in Pregnancy
    Darakjian, Lucy I.
    Kaddoumi, Amal
    MOLECULAR PHARMACEUTICS, 2019, 16 (03) : 1340 - 1349
  • [23] UNDERSTANDING THE PHARMACOKINETIC NONLINEARITY OF TABALUMAB BY INCORPORATING TARGET-MEDIATED DRUG DISPOSITION IN A PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL
    Zhou, Lian
    Han, Bing
    Radtke, David
    Witcher, Jennifer
    DRUG METABOLISM AND PHARMACOKINETICS, 2020, 35 (01) : S89 - S90
  • [24] Assessment of pharmacokinetic variations of capecitabine after multiple administration in rats: a physiologically based pharmacokinetic model
    Sakai, Shuhei
    Kobuchi, Shinji
    Ito, Yukako
    Sakaeda, Toshiyuki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (05) : 869 - 880
  • [25] Assessment of pharmacokinetic variations of capecitabine after multiple administration in rats: a physiologically based pharmacokinetic model
    Shuhei Sakai
    Shinji Kobuchi
    Yukako Ito
    Toshiyuki Sakaeda
    Cancer Chemotherapy and Pharmacology, 2020, 85 : 869 - 880
  • [26] A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs
    Davda, Jasmine P.
    Jain, Maneesh
    Batra, Surinder K.
    Gwilt, Peter R.
    Robinson, Dennis H.
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2008, 8 (03) : 401 - 413
  • [27] Physiologically Based Pharmacokinetic Model for T84.66: A Monoclonal Anti-CEA Antibody
    Urva, Shweta R.
    Yang, Victor C.
    Balthasar, Joseph P.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2010, 99 (03) : 1582 - 1600
  • [28] A Physiologically-Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics From In Vitro Data
    Jones, Hannah M.
    Zhang, Zhiwei
    Jasper, Paul
    Luo, Haobin
    Avery, Lindsay B.
    King, Lindsay E.
    Neubert, Hendrik
    Barton, Hugh A.
    Betts, Alison M.
    Webster, Robert
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2019, 8 (10): : 738 - 747
  • [29] Prediction of Drug–Drug Interactions After Esketamine Intranasal Administration Using a Physiologically Based Pharmacokinetic Model
    Marie-Emilie Willemin
    Peter Zannikos
    Geert Mannens
    Loeckie de Zwart
    Jan Snoeys
    Clinical Pharmacokinetics, 2022, 61 : 1115 - 1128
  • [30] Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration
    Zheng, Yanan
    Tesar, Devin B.
    Benincosa, Lisa
    Birnboeck, Herbert
    Boswell, C. Andrew
    Bumbaca, Daniela
    Cowan, Kyra J.
    Danilenko, Dimitry M.
    Daugherty, Ann L.
    Fielder, Paul J.
    Grimm, Hans Peter
    Joshi, Amita
    Justies, Nicole
    Kolaitis, Gerry
    Lewin-Koh, Nicholas
    Li, Jing
    McVay, Sami
    O'Mahony, Jennifer
    Otteneder, Michael
    Pantze, Michael
    Putnam, Wendy S.
    Qiu, Zhihua J.
    Ruppel, Jane
    Singer, Thomas
    Stauch, Oliver
    Theil, Frank-Peter
    Visich, Jennifer
    Yang, Jihong
    Ying, Yong
    Khawli, Leslie A.
    Richter, Wolfgang F.
    MABS, 2012, 4 (02) : 243 - 255